adamantane has been researched along with Cardiovascular Diseases in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 48 (94.12) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Poonchuay, N; Uitrakul, S; Wattana, K | 1 |
| Morinobu, A | 1 |
| Gallo, M; Giaccari, A; Mannucci, E; Monami, M; Montereggi, C; Nreu, B; Ragghianti, B | 1 |
| Bergenheim, K; Bhatt, DL; Briggs, AH; Hirshberg, B; Johnston, KM; Mosenzon, O; Mukherjee, J; Raz, I; Scirica, BM; Szabo, SM | 1 |
| Billger, M; Boulton, DW; Chadwick, KD; Hirshberg, B; Iqbal, N; Pollack, PS; Smith, DM | 1 |
| Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA | 1 |
| Allen, E; Bryzinski, B; Cook, W; Frederich, R; Slater, J | 1 |
| Mahler, RJ | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Davidson, J; Desai, NR; Frederich, R; Hirshberg, B; Hoffman, EB; Leiter, LA; McGuire, DK; Mosenzon, O; Ohman, P; Ray, KK; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Wiviott, SD | 1 |
| Cohen, D | 1 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Mitka, M | 1 |
| Montori, VM; Morey-Vargas, OL | 1 |
| Bhatt, DL; Braunwald, E; Scirica, BM | 1 |
| Standl, E | 1 |
| Donovan, M; Frederich, R; Hirshberg, B; Iqbal, N; Parker, A | 1 |
| Mullard, A | 1 |
| Dunn, A | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Davis, TM | 1 |
| Avogaro, A; Dardano, A; de Kreutzenberg, SV; Del Prato, S | 1 |
| Bhatt, DL; Buskila, A; Greenberger, N; Hirshberg, B; Im, K; Iqbal, N; Lerch, MM; Mosenzon, O; Raz, I; Scirica, BM; Stahre, C; Umez-Eronini, A | 1 |
| Gallwitz, B; Nitschmann, S | 1 |
| Bryzinski, B; Cook, W; Hirshberg, B; Minervini, G | 1 |
| Bhatt, DL; Braunwald, E; Cavender, MA; Corbalan, R; Davidson, JA; Frederich, R; He, P; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Nicolau, JC; Raz, I; Scirica, BM; Steg, PG; Udell, JA; Umez-Eronini, AA | 1 |
| Toth, PP | 1 |
| Dangi-Garimella, S | 1 |
| Hirayama, A; Nagao, K; Takahashi, A; Tani, S | 1 |
| Burciu, C; Koska, J; Reaven, P; Sands, M | 1 |
| Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L | 1 |
| Baruah, MP; Gupta, A; Gupta, Y; Kalra, S | 1 |
| Federici, M; Kappel, BA; Marx, N | 1 |
| Del Prato, S; Evans, M; Kothny, W; Lukashevich, V; McInnes, G; Schweizer, A; Shao, Q; Stumvoll, M | 1 |
| Bhatt, DL; Braunwald, E; Cahn, A; Cavender, MA; Davidson, J; Hirshberg, B; Im, K; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Scirica, BM; Steg, PG | 1 |
| Jain, R | 1 |
| Baker, WL; White, WB | 1 |
| Bonora, E; Bryzinski, B; Cook, W; Hirshberg, B | 1 |
| Cahn, A; Raz, I; Schernthaner, G | 1 |
| Cho, YM; Jang, HC; Jung, HS; Kim, SY; Kwak, S; Park, KS | 1 |
| Hernández, C; Simó, R | 1 |
| Mannucci, E; Monami, M | 1 |
| Dong, H; Gu, S; Hu, X; Yu, D; Zeng, Y | 1 |
| Boudes, P; Viereck, C | 1 |
| Jellinger, PS | 1 |
| Dicker, D | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
| Schwartz, SL | 1 |
| Cobble, ME; Frederich, R | 1 |
19 review(s) available for adamantane and Cardiovascular Diseases
| Article | Year |
|---|---|
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Disease Risk Factors; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Time Factors; Treatment Outcome | 2021 |
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Topics: Adamantane; Animals; Cardiotoxins; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic | 2017 |
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic | 2014 |
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemia; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Quality of Life; Vildagliptin | 2015 |
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.
Topics: Adamantane; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil | 2015 |
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones | 2015 |
Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Retrospective Studies; Vildagliptin | 2015 |
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil | 2016 |
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil | 2017 |
Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.
Topics: Adamantane; Asian People; Cardiovascular Diseases; China; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Male; Metformin; Models, Economic; Quality of Life | 2016 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrrolidines; Risk Factors; Vildagliptin | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Risk | 2012 |
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Patient Safety; Proportional Hazards Models; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
9 trial(s) available for adamantane and Cardiovascular Diseases
| Article | Year |
|---|---|
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index | 2013 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Thiazolidinediones | 2013 |
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Topics: Adamantane; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Hypoglycemia; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatitis | 2013 |
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis; Prognosis; Risk Factors | 2014 |
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Topics: Adamantane; Adult; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fasting; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Risk Factors | 2014 |
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Renal Insufficiency; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Topics: Adamantane; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Middle Aged; Nitriles; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrrolidines; Time Factors; Treatment Outcome; Vildagliptin | 2015 |
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Topics: Adamantane; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incretins; Male; Middle Aged; Myocardial Infarction; Risk; Stroke | 2016 |
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.
Topics: Adamantane; Cardiovascular Diseases; Chemokine CXCL12; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2017 |
23 other study(ies) available for adamantane and Cardiovascular Diseases
| Article | Year |
|---|---|
Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Nitriles; Risk Factors; Thailand; Treatment Outcome; Vildagliptin | 2022 |
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.
Topics: Adamantane; Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Hospitalization; Humans; Hypoglycemia; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2017 |
Commentary.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male | 2013 |
New oral hypoglycaemics fail to show cardiovascular benefits.
Topics: Adamantane; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic; Treatment Failure; Uracil | 2013 |
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2013 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Outcome results renew debate about diabetes drug development.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Treatment Outcome; Uracil | 2013 |
In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male | 2014 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Piperidines; Uracil | 2014 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration | 2014 |
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2015 |
Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Female; Humans; Male; Renal Insufficiency | 2015 |
A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Piperidines; Risk Factors; Sitagliptin Phosphate; Uracil | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |